Tags

Type your tag names separated by a space and hit enter

Antiviral treatment for COVID-19: the evidence supporting remdesivir.
Clin Med (Lond). 2020 11; 20(6):e215-e217.CM

Abstract

The emergence of the novel beta coronavirus SARS-CoV-2 and the ensuing COVID-19 pandemic has generated a rapidly evolving research landscape in the search for new therapeutic agents. The intravenous antiviral drug remdesivir has in vitro activity against SARS-CoV-2 and now studies have reported its clinical efficacy, demonstrating shorter time to recovery in hospitalised patients with severe COVID-19. Adverse event rates were low and remdesivir has now received conditional marketing authorisation from the European Medicines Agency. An interim clinical commissioning policy is in place in the UK. These studies make remdesivir the first antiviral drug able to alter the natural history of severe COVID-19, and a benchmark for the comparison of new therapies in the future. Ongoing studies are investigating its use in early mild/moderate COVID-19, alternative formulations, and the combination of remdesivir with immunomodulatory agents.

Authors+Show Affiliations

Royal Free London NHS Foundation Trust charlotterichardson1@nhs.net.Royal Free London NHS Foundation Trust, and honorary senior lecturer, University College London.Royal Free London NHS Foundation Trust, and Wellcome Trust postdoctoral clinical research fellow and NIHR clinical lecturer, University College London.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32863273

Citation

Richardson, Charlotte, et al. "Antiviral Treatment for COVID-19: the Evidence Supporting Remdesivir." Clinical Medicine (London, England), vol. 20, no. 6, 2020, pp. e215-e217.
Richardson C, Bhagani S, Pollara G. Antiviral treatment for COVID-19: the evidence supporting remdesivir. Clin Med (Lond). 2020;20(6):e215-e217.
Richardson, C., Bhagani, S., & Pollara, G. (2020). Antiviral treatment for COVID-19: the evidence supporting remdesivir. Clinical Medicine (London, England), 20(6), e215-e217. https://doi.org/10.7861/clinmed.2020-0524
Richardson C, Bhagani S, Pollara G. Antiviral Treatment for COVID-19: the Evidence Supporting Remdesivir. Clin Med (Lond). 2020;20(6):e215-e217. PubMed PMID: 32863273.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antiviral treatment for COVID-19: the evidence supporting remdesivir. AU - Richardson,Charlotte, AU - Bhagani,Sanjay, AU - Pollara,Gabriele, Y1 - 2020/08/30/ PY - 2020/8/31/pubmed PY - 2020/12/1/medline PY - 2020/9/1/entrez KW - COVID-19 KW - antiviral KW - remdesivir SP - e215 EP - e217 JF - Clinical medicine (London, England) JO - Clin Med (Lond) VL - 20 IS - 6 N2 - The emergence of the novel beta coronavirus SARS-CoV-2 and the ensuing COVID-19 pandemic has generated a rapidly evolving research landscape in the search for new therapeutic agents. The intravenous antiviral drug remdesivir has in vitro activity against SARS-CoV-2 and now studies have reported its clinical efficacy, demonstrating shorter time to recovery in hospitalised patients with severe COVID-19. Adverse event rates were low and remdesivir has now received conditional marketing authorisation from the European Medicines Agency. An interim clinical commissioning policy is in place in the UK. These studies make remdesivir the first antiviral drug able to alter the natural history of severe COVID-19, and a benchmark for the comparison of new therapies in the future. Ongoing studies are investigating its use in early mild/moderate COVID-19, alternative formulations, and the combination of remdesivir with immunomodulatory agents. SN - 1473-4893 UR - https://www.unboundmedicine.com/medline/citation/32863273/Antiviral_treatment_for_COVID_19:_the_evidence_supporting_remdesivir_ L2 - https://www.rcpjournals.org/lookup/pmid/32863273 DB - PRIME DP - Unbound Medicine ER -